Telomir Pharmaceuticals Secures $3 Million Investment to Advance Novel Age-Reversal Drug for Rare Diseases
• Telomir Pharmaceuticals has secured $3 million in premium equity financing from its largest shareholder to advance Telomir-1, a first-in-class age-reversal molecule, toward an IND submission for rare disease indications by year-end.
• The company's lead candidate, Telomir-1, targets five fundamental biological drivers of aging and has shown promising preclinical results across multiple conditions including Progeria, Wilson's disease, and Type 2 diabetes.
• Telomir is also developing Telomir-Ag2, a novel stabilized Silver(II) compound with broad-spectrum antimicrobial activity against drug-resistant pathogens, addressing a global market projected to exceed $30 billion.
Newron Pharmaceuticals Advances Pivotal Phase III Program for Treatment-Resistant Schizophrenia
• Newron Pharmaceuticals has received regulatory approval for its ENIGMA-TRS Phase III program evaluating Evenamide as an add-on therapy for treatment-resistant schizophrenia, with patient recruitment beginning immediately.
• The pivotal program consists of two studies designed to meet requirements for marketing authorization in major markets including the USA and Europe, with results expected by late 2026.
• Evenamide, a first-in-class glutamate modulator, has shown promising results in earlier trials with 70% of TRS patients experiencing clinically significant benefits and 25% achieving remission during one-year treatment.
Telomir Pharmaceuticals Develops Novel Silver(II) Antimicrobial to Combat Drug-Resistant Infections
• Telomir Pharmaceuticals has developed Telomir-Ag2, a stabilized Silver(II) complex showing potent activity against drug-resistant pathogens including MARSA, targeting the $30B+ antimicrobial market.
• The breakthrough leverages Telomir's proprietary platform to stabilize highly reactive Silver(II) in a biologically compatible form, overcoming a major limitation that has historically prevented its medical use.
• Telomir-Ag2 demonstrated superior efficacy compared to Silver(I) compounds in preclinical studies, potentially addressing urgent needs in wound care and hospital-acquired infections that cause over 10,000 deaths annually in the US alone.
Telomir-1 Shows Complete Reversal of Oxidative Stress in Breakthrough Preclinical Study
• Telomir Pharmaceuticals' novel compound Telomir-1 demonstrates complete reversal of copper-induced oxidative stress in human cell lines, showing potential for treating age-related diseases and neurological disorders.
• The drug exhibits strong cellular protection against copper toxicity at low doses, suggesting a unique regulatory mechanism that could transform treatments for conditions like Wilson's Disease, Alzheimer's, and AMD.
• Researchers are exploring Telomir-1's potential application in treating viral infections, including avian influenza, where oxidative stress plays a crucial role in disease progression.
Telomir Pharmaceuticals' Telomir-1 Shows Copper-Binding Potential for Wilson's Disease Treatment
• Telomir Pharmaceuticals' Telomir-1 demonstrated significant copper-binding affinity in preclinical studies, suggesting its potential for treating Wilson's disease.
• The company plans IND-enabling safety studies in Q2 2025, targeting an IND submission by Q4 2025, with human clinical trials expected in H1 2026.
• Telomir discontinued an osteoarthritis study in dogs due to ethical concerns, opting for a new study design with naturally affected elderly dogs.
• The company is also expanding research into Type 2 diabetes, Progeria, cancer, and Alzheimer's, supported by recent financing secured at a 20% premium.
Three Biotech Firms Secure $700M in Major IPO Wave, Signaling Market Momentum
• Bicara Therapeutics leads the IPO surge with a $315 million raise for its cancer therapeutics program, marking the third-largest biotech IPO of 2024.
• Zenas BioPharma successfully raised $225 million to advance its immunology pipeline, while MBX Biosciences secured $163 million for endocrine and metabolic disease research.
• The triple IPO event represents a significant milestone in 2024's biotech market, though overall IPO activity remains below pre-pandemic levels with 18 biotechs going public this year.
© Copyright 2025. All Rights Reserved by MedPath